Outer membrane particles from Gram-negative bacteria are attractive vaccine candidates as they present surface antigens in their natural environment and orientation. We previously developed a high yield production process for genetically derived particles, called Generalized Modules for Membrane Antigens (GMMA), from Shigella. As GMMA are derived from the outer membrane and contain immune-stimulatory components, especially lipopoly-saccharide (LPS), we examined ways of reducing their reactogenicity by modifying lipid A, the endotoxic part of LPS, through deletion of late acyltransferase genes msbB or htrB in GMMA-producing S. sonnei and S. flexneri strains. GMMA with resulting penta-acylated lipid A from the msbB mutants showed a 600-fold reduction, GMMA from the S. sonnei ?htrB mutant a 60,000-fold reduced ability compared to GMMA with wild-type lipid A to stimulated human Toll-like receptor 4 (TLR4) in a reporter cell line. In contrast, in the S. flexneri ?htrB mutant, a compensatory palmitoleoylation occurs resulting in hexa-acylated lipid A with approximately 10-fold higher activity than the penta-acylated lipid A. In human PBMC, GMMA with penta-acylated lipid A showed a marked reduction in induction of inflammatory cytokines (800-fold for S. sonnei ?htrB, 300-fold for the msbB mutants) compared to a 50-fold reduction observed for GMMA with palmitoleoylated lipid A from the S. flexneri ?htrB strain. We demonstrated that the residual activity of GMMA with penta-acylated lipid A is largely due to non-lipid A related TLR2 activation whereas GMMA with palmitoleoylated hexa-acylated lipid A predominantly activate TLR4. These results identify the relative activation of TLR4 and TLR2 pathways by GMMA.

MODULATION OF REACTOGENICITY OF GENERALIZED MODULES FOR MEMBRANE ANTIGENS (GMMA)BY GENETIC LIPID A MODIFICATION

2014

Abstract

Outer membrane particles from Gram-negative bacteria are attractive vaccine candidates as they present surface antigens in their natural environment and orientation. We previously developed a high yield production process for genetically derived particles, called Generalized Modules for Membrane Antigens (GMMA), from Shigella. As GMMA are derived from the outer membrane and contain immune-stimulatory components, especially lipopoly-saccharide (LPS), we examined ways of reducing their reactogenicity by modifying lipid A, the endotoxic part of LPS, through deletion of late acyltransferase genes msbB or htrB in GMMA-producing S. sonnei and S. flexneri strains. GMMA with resulting penta-acylated lipid A from the msbB mutants showed a 600-fold reduction, GMMA from the S. sonnei ?htrB mutant a 60,000-fold reduced ability compared to GMMA with wild-type lipid A to stimulated human Toll-like receptor 4 (TLR4) in a reporter cell line. In contrast, in the S. flexneri ?htrB mutant, a compensatory palmitoleoylation occurs resulting in hexa-acylated lipid A with approximately 10-fold higher activity than the penta-acylated lipid A. In human PBMC, GMMA with penta-acylated lipid A showed a marked reduction in induction of inflammatory cytokines (800-fold for S. sonnei ?htrB, 300-fold for the msbB mutants) compared to a 50-fold reduction observed for GMMA with palmitoleoylated lipid A from the S. flexneri ?htrB strain. We demonstrated that the residual activity of GMMA with penta-acylated lipid A is largely due to non-lipid A related TLR2 activation whereas GMMA with palmitoleoylated hexa-acylated lipid A predominantly activate TLR4. These results identify the relative activation of TLR4 and TLR2 pathways by GMMA.
2014
it
File in questo prodotto:
File Dimensione Formato  
Thesis_ORO.pdf

accesso solo da BNCF e BNCR

Tipologia: Altro materiale allegato
Licenza: Tutti i diritti riservati
Dimensione 23.51 MB
Formato Adobe PDF
23.51 MB Adobe PDF

I documenti in UNITESI sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/20.500.14242/318329
Il codice NBN di questa tesi è URN:NBN:IT:BNCF-318329